Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dana-Farber Cancer Institute
Subjects will receive standard treatment for autologous stem cell transplant. Subjects will be assigned to receive no Eltrombopag or one of three dose levels of Eltrombopag. Subjects will receive oral Eltrombopag on days 2-15 of treatment.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Multiple myeloma
Stable or responsive disease after at least 2 cycles of conventional chemotherapy
Slated to undergo autologous peripheral blood stem cell transplant
Normal organ and marrow function
You may not be if
Myocardial infarction within 6 months of treatment
Receiving other study agents
Pregnant or breastfeeding
Uncontrolled intercurrent illness
Evidence of active or recent history of thromboembolic disease
Previous history of primary platelet disorder or bleeding disorder
History of a different malignancy unless disease free for at least 5 years
